AMGN Amgen Inc.

Healthcare · Drug Manufacturers - General

4 · Weak Momentum 10.0 · Strong Watch 14y streak

414.61

+2.11%

About the company

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Website Annual reports (10-K)

2.43%

62.53%

10.08

224.2B

25.72

16.12

361.66

52-week range

415

low 270 high 447

Dividend deep dive

Amgen Inc., a healthcare company in Drug Manufacturers - General, currently offers a dividend yield of 2.61% in USD. This is below its 5-year average yield of 3.16%, and outside its 5-year range of 2.99% to 3.43%. The company holds an overall rating score of 6.0. Its momentum score is 7.0, reflecting a positive price trend, while its value score is 5.0, indicating a balanced but not particularly cheap valuation.

Dividend history

Amgen has consistently increased its dividend for 14 consecutive years, earning it a 'Contender' status in the CCC list. Over the last three years, the dividend compounded at 7.05%, and over five years, it grew at 8.27% annually. The annual dividend per share in USD has been: 2.44 (2014), 3.16 (2015), 4.00 (2016), 4.60 (2017), 5.28 (2018), 5.80 (2019), 6.40 (2020), 7.04 (2021), 7.76 (2022), 8.52 (2023), 9.00 (2024), and 9.52 (2025).

Dividend safety

The dividend safety status is currently designated as 'watch.' Amgen's dividend payout ratio stands at 62.69% of its earnings per share, indicating a substantial portion of earnings is distributed.

Quantic · Free

Read the rest of the safety verdict

Plus the key risks and what to watch next — free, no card.

Try a sample portfolio Sign up free

AI-generated from Quantic's dividend data · Updated 21 Sep 2026 · Information, not financial advice.